Medication info
Tabarozet Tablets 2/10 Milligrams

Tabarozet Tablets 2/10 Milligrams

Prescription medicationTabletOral
Ingredient · strength
Pitavastatin Calcium›2mg / 1 tabletEzetimibe›10mg / 1 tablet
Manufacturer / importer
Daewon Pharmaceutical Co., Ltd.
Appearance
Yellow oval film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202301672 · Approved 2023.05.25 · Insurance code 671807710

Summary

Main use
Improvement of primary hypercholesterolemia and mixed dyslipidemia
Who takes it
Adults
Adult dose
Adults Administer this medicine once daily, regardless of meals. Patients must continue a standard cholesterol-lowering diet before and during treatment with this medicine. The dose of this medicine should be adjusted according to the patient's baseline LDL cholesterol level, recommended treatment goal, and response. The recommended initial dose is 2/10mg once daily. If the reduction in LDL cholesterol is insufficient, the dose may be increased to a maximum of 4/10mg once daily. Adjust the dose as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, the treatment goal, and the patient's response. Patients taking pitavastatin calcium and ezetimibe concomitantly may switch to this medicine (a combination product with the same amounts of each active ingredient) for convenience. Use in patients with hepatic impairment: In patients with hepatic impairment, an initial dose of 1 mg once daily of pitavastatin calcium is recommended; therefore, use of this medicine (a pitavastatin calcium/ezetimibe combination) as initial therapy is not recommended. The maximum dose is 2/10mg once daily. Use of this medicine (a pitavastatin calcium/ezetimibe combination) is not recommended in patients with moderate hepatic impairment. Do not administer this medicine (a pitavastatin calcium/ezetimibe combination) to patients with severe hepatic impairment.

Ingredients

Manufacturer
Daewon Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of primary hypercholesterolemia and mixed dyslipidemia

  • Primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • non-familial hypercholesterolemia
  • mixed dyslipidemia
  • elevated total cholesterol
  • elevated LDL cholesterol
  • elevated Apo B protein
  • elevated triglycerides
  • elevated non-HDL cholesterol
View approved original text

This medication is used to improve blood lipid levels in patients with primary hypercholesterolemia, particularly heterozygous familial and non-familial hypercholesterolemia, and mixed dyslipidemia. Specifically, it lowers levels of total cholesterol, LDL cholesterol, Apo B protein, triglycerides, and non-HDL cholesterol, while increasing levels of HDL cholesterol, which is the good cholesterol. It is administered as an adjunct to dietary therapy to improve overall blood lipid status.

How to take

Adult dose

Adults Administer this medicine once daily, regardless of meals. Patients must continue a standard cholesterol-lowering diet before and during treatment with this medicine. The dose of this medicine should be adjusted according to the patient's baseline LDL cholesterol level, recommended treatment goal, and response. The recommended initial dose is 2/10mg once daily. If the reduction in LDL cholesterol is insufficient, the dose may be increased to a maximum of 4/10mg once daily. Adjust the dose as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, the treatment goal, and the patient's response. Patients taking pitavastatin calcium and ezetimibe concomitantly may switch to this medicine (a combination product with the same amounts of each active ingredient) for convenience. Use in patients with hepatic impairment: In patients with hepatic impairment, an initial dose of 1 mg once daily of pitavastatin calcium is recommended; therefore, use of this medicine (a pitavastatin calcium/ezetimibe combination) as initial therapy is not recommended. The maximum dose is 2/10mg once daily. Use of this medicine (a pitavastatin calcium/ezetimibe combination) is not recommended in patients with moderate hepatic impairment. Do not administer this medicine (a pitavastatin calcium/ezetimibe combination) to patients with severe hepatic impairment.

Precautions

This medication should not be administered to certain patients. For example, it is contraindicated in patients with allergies to its components, patients with active liver disease, patients with severe liver dysfunction, patients taking cyclosporine, patients with myopathy, pregnant or breastfeeding women, and it should not be used in children due to lack of experience. Additionally, caution should be exercised in patients with reduced liver function or excessive alcohol consumption, those with renal dysfunction, patients with hypothyroidism, elderly patients, and patients with myasthenia. While taking this medication, symptoms such as muscle pain, weakness, abdominal pain, headache, fatigue, rash, or dyspepsia may occur, and immediate medical attention should be sought if symptoms arise. Serious muscle-related side effects such as myopathy or rhabdomyolysis can occur, so if symptoms of muscle pain or weakness develop, the medication should be discontinued immediately, and a doctor should be consulted. As this medication can affect liver function, regular liver function tests should be conducted before and during treatment, and if liver enzyme levels become abnormally high, the medication should be stopped. This medication may interact with other drugs, so it is essential to inform healthcare professionals about any current medications, especially if you are also taking cyclosporine, fibrates, nicotinic acid, or erythromycin. Pregnant or breastfeeding women should not take this medication, and women who may become pregnant must confirm pregnancy before use. Children and the elderly are at higher risk for side effects while taking this medication, so extra caution is warranted, with elderly patients potentially needing dose adjustments if adverse reactions occur. In case of overdose, there is no specific antidote, so management should involve supportive care and monitoring of liver function and blood tests based on symptoms. This medication should be kept out of the reach of children and should not be transferred to other containers to ensure safety and maintain quality.

Side effects

  • Abdominal pain
  • diarrhea
  • dry mouth
  • abdominal distension
  • gastroesophageal reflux disease
  • toothache
  • increased blood creatine phosphokinase
  • increased alanine aminotransferase
  • increased aspartate aminotransferase
  • weakness
Show 88 more
  • chest discomfort
  • fatigue
  • myalgia
  • dysgeusia
  • headache
  • urticaria
  • dizziness
  • decreased appetite
  • insomnia
  • dyspnea
  • constipation
  • dryness
  • rash
  • pruritus
  • lethargy
  • paralysis
  • thrombocytopenia
  • rigidity
  • drowsiness
  • dry mouth
  • dyspepsia
  • abdominal bloating
  • stomatitis
  • vomiting
  • anorexia
  • glossitis
  • nausea
  • gastric discomfort
  • thrombocytopenia
  • granulocytopenia
  • leukopenia
  • eosinophilia
  • leukocytosis
  • increased globulin
  • anemia
  • polyuria
  • elevated BUN
  • increased serum creatinine
  • decreased aldosterone
  • increased aldosterone
  • elevated adrenocorticotropic hormone
  • increased cortisol
  • decreased testosterone
  • muscle cramps
  • increased myoglobin
  • palpitations
  • skin tenderness
  • burning sensation
  • arthralgia
  • edema
  • blurred vision
  • photophobia
  • hearing loss
  • hematuria
  • elevated uric acid levels
  • increased serum potassium and phosphorus
  • colored urine
  • dizziness
  • sensory loss
  • anaphylaxis
  • erythema multiforme
  • cholelithiasis
  • cholecystitis
  • upper respiratory infection
  • cough
  • sputum
  • rhinorrhea
  • limb pain
  • diabetes
  • hypoglycemia
  • anemia
  • splenomegaly
  • hyperhidrosis
  • epigastric discomfort
  • belching
  • gastrointestinal disturbance
  • tongue disorders
  • palpitations
  • congestive heart failure
  • myocardial ischemia
  • flushing
  • renal failure
  • liver dysfunction
  • increased blood creatinine
  • elevated blood pressure
  • increased blood urea
  • increased CPK
  • abnormal liver function tests

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light and should be stored in an opaque container. Additionally, it is important to maintain a temperature between 1 and 30 degrees Celsius when storing the medication to preserve its effectiveness.

Appearance and packaging

Appearance

Yellow oval film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.